NASDAQ:ENDP Endo International (ENDP) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free ENDP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0008▼$0.000950-Day Range$0.28▼$0.7552-Week Range$0.28▼$7.07Volume62,476 shsAverage Volume28.19 million shsMarket Capitalization$188,114.40P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaSustainabilityStock AnalysisCompetitorsHeadlinesSocial MediaSustainability Get Endo International alerts: Email Address Endo International MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainability-2.62Upright™ Environmental ScoreNews Sentiment0.01Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth-83.33%From $0.78 to $0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.09 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Endo International. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ENDP. Previous Next 0.0 Dividend Strength Dividend YieldEndo International does not currently pay a dividend.Dividend GrowthEndo International does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEndo International has received a 40.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Frovatriptan succinate", "Other cancer medication", "Isosorbide dinitrate", "Oxycodone", "Cyanocobalamin", and "Paracetamol" products. See details.Environmental SustainabilityThe Environmental Impact score for Endo International is -2.62. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for Endo International this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ENDP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Endo International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Endo International is held by insiders.Percentage Held by Institutions80.39% of the stock of Endo International is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Endo International are expected to decrease by -83.33% in the coming year, from $0.78 to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Endo International Stock (NASDAQ:ENDP)Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.Read More Ad Monument Traders AllianceMake This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00 ENDP Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comEndo International plc (ENDP)March 15, 2024 | bitcoinist.comXRP Scores Regulatory Win: European Governance Institute Endorses Non-Security StatusMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 13, 2024 | financialpost.comAmerican Perceptions Shift from Skepticism to Endorsement with Direct AI Engagement, according to Insurity’s 2024 AI in Insurance ReportMarch 12, 2024 | bitcoinist.comRap Star Drake Brings Bitcoin To The Masses With Saylor VideoMarch 9, 2024 | benzinga.comFormer House Speaker Nancy Pelosi Labels Mitch McConnell's Trump Endorsement As 'Sad, Professional Tragedy'March 8, 2024 | wsj.comEndo’s Chapter 11 Plan Has Unusual Provision Leaving Door Open to LitigationMarch 7, 2024 | rttnews.comNikki Haley Quits GOP Presidential Race Without Endorsing Trump March 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 2, 2024 | financialpost.comHaley Gets First Senate GOP Endorsements From Murkowski, CollinsFebruary 29, 2024 | msn.comPa. drugmaker Endo agreed to pay up to $465 million to settle criminal and civil claims related to opioid marketingFebruary 29, 2024 | reuters.comDrugmaker Endo reaches $465 mln bankruptcy settlement with US governmentFebruary 25, 2024 | benzinga.comEndo International Stock (OTC:ENDPQ) Dividends: History, Yield and DatesFebruary 21, 2024 | financialpost.comSeizing Frozen Russian Assets Over Ukraine War Wins Endorsement of Legal ExpertsFebruary 14, 2024 | wsj.comThe Small University Endowment That Is Beating the Ivy LeaguesFebruary 13, 2024 | benzinga.comDonald Trump Wants Taylor Swift's Endorsement And Says He 'Likes Her Boyfriend' Travis Kelce —- 'Even Though He's A Liberal And Probably Can't Stand Me'February 10, 2024 | investorplace.comFebruary’s Phenoms: 3 Strong Buy Fintech Stocks Endorsed by Wall StreetFebruary 8, 2024 | bitcoinist.comBeware: Deepfake Exploits Vitalik Buterin’s Image In Sham Crypto Wallet EndorsementFebruary 7, 2024 | investorplace.comBUD Stock Pops as Trump Endorses Anheuser-BuschJanuary 22, 2024 | rttnews.comRon DeSantis Ends White House Bid, Endorses Trump January 20, 2024 | benzinga.comSenate Republicans Are Reportedly Feeling Pressure To Endorse Donald Trump Ahead Of Key PrimaryJanuary 15, 2024 | businesswire.comCanon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound SystemsJanuary 12, 2024 | insidebitcoins.comEthereum Price Prediction: As Vitalik Buterin Endorses Raising ETH’s Block Gas Limit, This New Presale Reveals The Secrets Of Web3 Crypto TradingJanuary 11, 2024 | 247cryptonews.comSEC Chair Gary Gensler Cautions Against Mistaking Spot Bitcoin ETF Approval as BTC EndorsementJanuary 10, 2024 | wsj.comEndo Wins Court Permission to Solicit Votes on Restructuring PlanJanuary 4, 2024 | benzinga.comChris Christie Expresses Regrets Endorsing Trump In 2016: 'I Did It Because He Was Winning'December 27, 2023 | benzinga.comTrump's New Buddy In 2024 Race? Ramaswamy Catches His Eye Despite TV Ad Pullback - 'He Will, I Am Sure, Endorse Me'See More Headlines Receive ENDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endo International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ENDP CUSIP29264F20 CIK1593034 Webwww.endo.com Phone(531) 268-2000Fax800-329-3636Employees3,103Year Founded1997Profitability EPS (Most Recent Fiscal Year)($11.07) Trailing P/E RatioN/A Forward P/E Ratio0.00 P/E GrowthN/ANet Income$-613,240,000.00 Net Margins-93.31% Pretax Margin-91.14% Return on Equity-34.25% Return on Assets6.72% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.62 Sales & Book Value Annual Sales$2.99 billion Price / Sales0.00 Cash Flow$0.01 per share Price / Cash Flow0.06 Book Value($13.60) per share Price / Book0.00Miscellaneous Outstanding Shares235,143,000Free Float232,321,000Market Cap$188,114.40 OptionableNo Data Beta1.15 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Blaise A. Coleman (Age 48)Pres, CEO & Director Comp: $20.93MMr. Mark T. Bradley (Age 52)Exec. VP & CFO Comp: $6.27MMr. Matthew Joseph Maletta (Age 50)Exec. VP, Chief Legal Officer & Company Sec. Comp: $7.02MMr. Patrick A. Barry (Age 54)Exec. VP & Pres of Global Commercial Operations Comp: $6.15MFrank B. RacitiVP, Controller & Chief Accounting OfficerMs. Cheryl StouchSr. VP of Information Technology & Chief Information OfficerMs. Laure E. ParkSr. VP of Investor Relations & Corp. AffairsMs. Susan WilliamsonSr. VP & Chief Compliance OfficerMs. Tracy BassoChief HR OfficerMr. James PappHead of Endo Ventures Limited & Sr. VP of Global Supply ChainMore ExecutivesKey CompetitorsPanbela TherapeuticsNASDAQ:PBLATransCode TherapeuticsNASDAQ:RNAZScopus BioPharmaNASDAQ:SCPSCalithera BiosciencesNASDAQ:CALAAthersysNASDAQ:ATHXView All Competitors ENDP Stock Analysis - Frequently Asked Questions How were Endo International's earnings last quarter? Endo International plc (NASDAQ:ENDP) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.34. The company had revenue of $772.03 million for the quarter, compared to analysts' expectations of $667.94 million. Endo International had a negative net margin of 93.31% and a negative trailing twelve-month return on equity of 34.25%. Endo International's revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.52 EPS. What is Paul Campanelli's approval rating as Endo International's CEO? 25 employees have rated Endo International Chief Executive Officer Paul Campanelli on Glassdoor.com. Paul Campanelli has an approval rating of 86% among the company's employees. What other stocks do shareholders of Endo International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA). This page (NASDAQ:ENDP) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endo International plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.